MARKET

SAGE

SAGE

Sage Therapeutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.93
+0.26
+0.82%
After Hours: 31.93 0 0.00% 16:08 05/26 EDT
OPEN
31.85
PREV CLOSE
31.67
HIGH
32.86
LOW
31.84
VOLUME
332.01K
TURNOVER
0
52 WEEK HIGH
79.45
52 WEEK LOW
27.36
MARKET CAP
1.89B
P/E (TTM)
-3.8803
1D
5D
1M
3M
1Y
5Y
8 Analysts Have This to Say About Sage Therapeutics
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:
Benzinga · 2d ago
Goldman Sachs Lowers Sage Therapeutics' Price Target to $73 From $85, Maintains Buy Rating
MT Newswires · 2d ago
Insiders in Sage Therapeutics, Inc. (NASDAQ:SAGE) are down 32% on their US$2.9m purchase despite recent gains
Insiders who bought US$2.9m worth of Sage Therapeutics, Inc. ( NASDAQ:SAGE ) stock in the last year recovered part of...
Simply Wall St. · 3d ago
Sage Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase in earnings, the company posted a loss of $122.06 million.
Benzinga · 05/13 13:55
--Morgan Stanley Adjusts Sage Therapeutics' Price Target to $53 from $57, Keeps Equalweight Rating
MT Newswires · 05/10 12:49
Insider Buy: Sage Therapeutics
MT Newswires · 05/09 11:35
Analyst Ratings for Sage Therapeutics
Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade ...
Benzinga · 05/04 16:15
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
CAMBRIDGE, Mass., May 04, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the Bank of America Securities 2022...
Business Wire · 05/04 10:30
More
No Data
Learn about the latest financial forecast of SAGE. Analyze the recent business situations of Sage Therapeutic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

26.09%Strong Buy
21.74%Buy
52.17%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SAGE stock price target is 60.14 with a high estimate of 105.00 and a low estimate of 35.00.
High105.00
Average60.14
Low35.00
Current 31.93
EPS
Actual
Estimate
-1.77-1.33-0.88-0.44
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 380
Institutional Holdings: 60.63M
% Owned: 102.65%
Shares Outstanding: 59.07M
TypeInstitutionsShares
Increased
65
3.92M
New
35
854.99K
Decreased
70
3.51M
Sold Out
35
1.54M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Kevin Starr
President/Chief Executive Officer/Director
Barry Greene
Chief Financial Officer/Treasurer
Kimi Iguchi
Senior Vice President/General Counsel/Secretary
Anne Cook
Chief Scientific Officer
Albert Robichaud
Other/Director
Jeffrey Jonas
Other
Chris Benecchi
Other
Stephen Kanes
Independent Director
Elizabeth Barrett
Independent Director
Michael Cola
Independent Director
James Frates
Independent Director
Geno Germano
Independent Director
George Golumbeski
Independent Director
Steven Paul
No Data
No Data
About SAGE
SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.

Webull offers kinds of SAGE Therapeutics Inc stock information, including NASDAQ:SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAGE stock methods without spending real money on the virtual paper trading platform.